Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasis
Satoshi Takagi(Japanese Foundation For Cancer Research), Ryohei Katayama(Japanese Foundation For Cancer Research), Yosuke Seto, Mizuki Haraguchi, Masanori Saito(Japanese Foundation For Cancer Research), Ai Takemoto(Japanese Foundation For Cancer Research), Seiichi Matsumoto(Fukuda Denshi (Japan)), Takao Ukaji(Juntendo University), Yuki Sasaki, Keisuke Ae(The Cancer Institute Hospital), Minoru Sugawara, Tokuichi Kawaguchi(The Cancer Institute Hospital), Naoya Fujita(Japanese Foundation For Cancer Research), Sumie Koike, Yuki Funauchi(Japan Association for Development of Community Medicine)
Cited by 48
Related Papers
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
|Journal of Clinical Oncology|2012|1.6k
Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
|Nature Communications|2017|409
Clear Cell Sarcoma of Soft Tissue
|The American Journal of Surgical Pathology|2008|283
Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A
|Proceedings of the National Academy of Sciences|2018|264